2-AG + 2 new players = forecast for therapeutic advances.
In this issue of Chemistry & Biology, Blankman et al. identify new enzymes hydrolyzing the endocannabionoid 2-arachidonoyl glycerol (2-AG), increasing the complexity of endocannabinoid signaling in the brain, but also pinpointing additional therapeutic targets.
Marrs
William
W
Graduate Program in Neurobiology and Behavior, University of Washington, Seattle, WA 98195, USA.
Stella
Nephi
N
D000818:Animals; D001095:Arachidonic Acids / Q000378:metabolism*; D001921:Brain / Q000187:drug effects / Q000201:enzymology* / Q000378:metabolism; D063385:Cannabinoid Receptor Modulators / Q000378:metabolism; D002384:Catalysis / Q000187:drug effects; D063388:Endocannabinoids; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005989:Glycerides / Q000378:metabolism*; D006801:Humans; D008565:Membrane Proteins / Q000378:metabolism; D051379:Mice; D008954:Models, Biological; D008994:Monoacylglycerol Lipases / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D013347:Subcellular Fractions / Q000378:metabolism
D001095:Arachidonic Acids; D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D004791:Enzyme Inhibitors; D005989:Glycerides; D008565:Membrane Proteins; C094503:glyceryl 2-arachidonate; D008994:Monoacylglycerol Lipases